In this context, the present study demonstrates a previously unknown dual IL-1β-triggered mechanism of TF expression in lung cancer cells and thus defines upstream targets for pharmacotherapeutic intervention to block the formation of protumorigenic TF. The gene discussed is IL1B; the disease is lung cancer.